Literature DB >> 20337496

Phantasmidine: an epibatidine congener from the ecuadorian poison frog Epipedobates anthonyi.

Richard W Fitch1, Thomas F Spande, H Martin Garraffo, Herman J C Yeh, John W Daly.   

Abstract

The skin of the Ecuadorian poison frog Epipedobates anthonyi contains the potent nicotinic agonists epibatidine (1) and N-methylepibatidine (3). In addition, a condensed tetracyclic epibatidine congener has been identified with activity at nicotinic acetylcholine receptors, but different selectivity than epibatidine. This rigid tetracycle has been named phantasmidine (4). Phantasmidine has a molecular formula of C(11)H(11)N(2)OCl, shares a chloropyridine moiety with 1, and also contains furan, pyrrolidine, and cyclobutane rings. A combination of GC-MS and GC-FTIR analysis with on-column derivatization, 1D NMR spectroscopy with selective irradiation, and spectral simulation, along with 2D NMR, were used to elucidate the structure from a total sample of approximately 20 microg of HPLC-purified 4 and its corresponding acetamide (5). After synthesis, this novel rigid agonist may serve as a selective probe for beta4-containing nicotinic receptors and potentially lead to useful pharmaceuticals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20337496      PMCID: PMC2866194          DOI: 10.1021/np900727e

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  33 in total

1.  How do ring currents affect (1)h NMR chemical shifts?

Authors:  Chaitanya S Wannere; Paul Von Ragué Schleyer
Journal:  Org Lett       Date:  2003-03-06       Impact factor: 6.005

Review 2.  Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands.

Authors:  P C Astles; S R Baker; J R Boot; L M Broad; C P Dell; M Keenan
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-08

3.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

4.  6'-Methylpyrido[3,4-b]norhomotropane: synthesis and outstanding potency in relation to the alpha4beta2 nicotinic receptor pharmacophore model.

Authors:  David B Kanne; Motohiro Tomizawa; Kathleen A Durkin; John E Casida
Journal:  Bioorg Med Chem Lett       Date:  2005-02-15       Impact factor: 2.823

5.  Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit.

Authors:  Ramiro Salas; Fredalina Pieri; Mariella De Biasi
Journal:  J Neurosci       Date:  2004-11-10       Impact factor: 6.167

6.  Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity.

Authors:  M J Parker; A Beck; C W Luetje
Journal:  Mol Pharmacol       Date:  1998-12       Impact factor: 4.436

7.  [3H]cytisine binding to nicotinic cholinergic receptors in brain.

Authors:  L A Pabreza; S Dhawan; K J Kellar
Journal:  Mol Pharmacol       Date:  1991-01       Impact factor: 4.436

8.  Mice lacking neuronal nicotinic acetylcholine receptor beta4-subunit and mice lacking both alpha5- and beta4-subunits are highly resistant to nicotine-induced seizures.

Authors:  Merav Kedmi; Arthur L Beaudet; Avi Orr-Urtreger
Journal:  Physiol Genomics       Date:  2004-04-13       Impact factor: 3.107

Review 9.  Epibatidine: impact on nicotinic receptor research.

Authors:  Małgorzata Dukat; Richard A Glennon
Journal:  Cell Mol Neurobiol       Date:  2003-06       Impact factor: 5.046

10.  Characterization of curaremimetic neurotoxin binding sites on membrane fractions derived from the human medulloblastoma clonal line, TE671.

Authors:  R J Lukas
Journal:  J Neurochem       Date:  1986-06       Impact factor: 5.372

View more
  8 in total

1.  Synthesis of phantasmidine.

Authors:  Quan Zhou; Barry B Snider
Journal:  Org Lett       Date:  2010-12-22       Impact factor: 6.005

2.  Absolute Configuration and Pharmacology of the Poison Frog Alkaloid Phantasmidine.

Authors:  Richard W Fitch; Barry B Snider; Quan Zhou; Bruce M Foxman; Anshul A Pandya; Jerrel L Yakel; Thao T Olson; Nour Al-Muhtasib; Yingxian Xiao; Kevin D Welch; Kip E Panter
Journal:  J Nat Prod       Date:  2018-04-19       Impact factor: 4.050

3.  Trade-offs between cost of ingestion and rate of intake drive defensive toxin use.

Authors:  Tyler E Douglas; Sofia G Beskid; Callie E Gernand; Brianna E Nirtaut; Kristen E Tamsil; Richard W Fitch; Rebecca D Tarvin
Journal:  Biol Lett       Date:  2022-02-09       Impact factor: 3.703

Review 4.  Natural products as reservoirs of novel therapeutic agents.

Authors:  Sadaf Mushtaq; Bilal Haider Abbasi; Bushra Uzair; Rashda Abbasi
Journal:  EXCLI J       Date:  2018-05-04       Impact factor: 4.068

Review 5.  Microbial Pyrrolnitrin: Natural Metabolite with Immense Practical Utility.

Authors:  Shraddha Pawar; Ambalal Chaudhari; Ratna Prabha; Renu Shukla; Dhananjaya P Singh
Journal:  Biomolecules       Date:  2019-09-03

6.  The discriminative stimulus effects of epibatidine in C57BL/6J mice.

Authors:  Fernando B de Moura; Takato Hiranita; Lance R McMahon
Journal:  Behav Pharmacol       Date:  2020-09       Impact factor: 2.277

7.  Halogenation-Guided Chemical Screening Provides Insight into Tjipanazole Biosynthesis by the Cyanobacterium Fischerella ambigua.

Authors:  Tomasz Chilczuk; Till F Schäberle; Sahel Vahdati; Ute Mettal; Mustafa El Omari; Heike Enke; Michael Wiese; Gabriele M König; Timo H J Niedermeyer
Journal:  Chembiochem       Date:  2020-04-16       Impact factor: 3.164

Review 8.  Pyridine alkaloids with activity in the central nervous system.

Authors:  Simon X Lin; Maurice A Curtis; Jonathan Sperry
Journal:  Bioorg Med Chem       Date:  2020-10-16       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.